We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

That was the pseudonym taken by the Buccaneers quarterback during an episode of "The Undercovers," a show hosted by Eli Manning. For his episode, Mayfield donned a questionable disguise including ...

Earlier this week, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development, as the company inches closer to ...

EXCLUSIVE: Filming has wrapped on Dragn, an under-the-radar horror-sci-fi film, starring James Paxton (Twisters), Carlos Bardem (Assassin’s Creed), Lilly Krug (Plane) and Alice Pagani (Loro).

The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the ...

© 2004-2024 CBS Interactive. All rights reserved. CBS Sports is a registered trademark of CBS Broadcasting Inc. Commissioner.com is a registered trademark of CBS ...

Eli Lilly’s (NYSE:LLY) blockbuster GLP-1 medication, tirzepatide, is no longer in shortage in the U.S., the U.S. Food and Drug Administration (FDA) said on Wednesday. Tirzepatide, currently ...

The health regulator said it confirmed with Lilly that the current supply and manufacturing capacity could meet the present and projected national demand for the drug. Originally developed for ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have ...

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.